A Dravet therapy is testing a shift from seizure control to the gene

Zorevunersen has nothing to do with space. This is a medicine story about Dravet syndrome, a severe genetic epilepsy in children, most often linked to SCN1A haploinsufficiency. ScienceDaily, citing University College London, reports that the experimental therapy reduced seizures by up to 91 percent in early studies.

The clinical context matters. Dravet syndrome brings frequent seizures that are difficult to control, neurodevelopmental challenges, feeding and movement problems, and a higher risk of premature death. Standard antiseizure drugs do not fully control seizures in many patients, and they do not directly address the cognitive and behavioral complications of the disorder.

Zorevunersen is an antisense oligonucleotide designed to increase production of NaV1.1 sodium channels from the healthy copy of the SCN1A gene. In other words, the therapy is not only trying to dampen the electrical storm after it starts. It is trying to correct the protein shortfall that makes that storm more likely.

The paper in the New England Journal of Medicine describes two open-label multicenter phase 1-2a studies, MONARCH and ADMIRAL, enrolling patients aged 2 to 18 who were already receiving standard antiseizure medications. ScienceDaily says the initial and extension studies together involved 81 children, with 75 continuing into extensions dosed every four months.

Before treatment, patients averaged 17 seizures per month. The report describes seizure reductions of up to 91 percent, quality-of-life improvements, and early signals of benefit for thinking and behavior. Most reported side effects were mild, but that does not mean the safety profile is settled.

The main caveat is that the early studies were designed primarily to assess safety and tolerability. A larger Phase 3 trial is already underway and needs to answer questions about durability, rare side effects, optimal dosing, and which children benefit most. Until then, zorevunersen remains a promising intervention, not a new standard of care.

If Phase 3 confirms the findings, the shift would be real. Treatment for Dravet syndrome would move from symptom management toward targeting the biological cause. For families, that would not mean an abstract molecular victory, but potentially more seizure-free days, fewer emergencies, and a chance at steadier development.

For source context, compare NIH, FDA AI/ML devices and Wikipedia background.